NO20083968L - Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom - Google Patents
Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdomInfo
- Publication number
- NO20083968L NO20083968L NO20083968A NO20083968A NO20083968L NO 20083968 L NO20083968 L NO 20083968L NO 20083968 A NO20083968 A NO 20083968A NO 20083968 A NO20083968 A NO 20083968A NO 20083968 L NO20083968 L NO 20083968L
- Authority
- NO
- Norway
- Prior art keywords
- prevent
- receptor antagonists
- adenosine receptor
- hepatic disease
- treat hepatic
- Prior art date
Links
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 101150078577 Adora2b gene Proteins 0.000 title abstract 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 206010019799 Hepatitis viral Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 206010001584 alcohol abuse Diseases 0.000 abstract 1
- 208000025746 alcohol use disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 231100000334 hepatotoxic Toxicity 0.000 abstract 1
- 230000003082 hepatotoxic effect Effects 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 238000011477 surgical intervention Methods 0.000 abstract 1
- 201000001862 viral hepatitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78357506P | 2006-03-17 | 2006-03-17 | |
| PCT/US2007/064182 WO2007109547A2 (en) | 2006-03-17 | 2007-03-16 | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083968L true NO20083968L (no) | 2008-12-15 |
Family
ID=38514256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083968A NO20083968L (no) | 2006-03-17 | 2008-09-17 | Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7795268B2 (enExample) |
| EP (1) | EP1996201A2 (enExample) |
| JP (2) | JP5250848B2 (enExample) |
| KR (1) | KR101428113B1 (enExample) |
| CN (1) | CN101405003B (enExample) |
| AU (1) | AU2007227021B2 (enExample) |
| CA (2) | CA2646333C (enExample) |
| IL (1) | IL194158A0 (enExample) |
| MX (1) | MX2008011828A (enExample) |
| NO (1) | NO20083968L (enExample) |
| NZ (1) | NZ571324A (enExample) |
| RU (1) | RU2457842C2 (enExample) |
| WO (1) | WO2007109547A2 (enExample) |
| ZA (1) | ZA200807894B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US20080194593A1 (en) * | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| EP2311462A1 (en) | 2004-10-15 | 2011-04-20 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| US7598379B2 (en) * | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| CA2646333C (en) | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| WO2009055021A1 (en) * | 2007-10-26 | 2009-04-30 | New York University School Of Medicine | Methods and compositions for treating hepatic diseases |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
| EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| US20140142113A1 (en) * | 2012-11-09 | 2014-05-22 | Michael W. Burnet | Method of treating inflammatory diseases using adenosine 2b receptor antagonists |
| US10583102B2 (en) | 2014-10-06 | 2020-03-10 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
| WO2016129760A1 (ko) * | 2015-02-13 | 2016-08-18 | 한국과학기술원 | Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물 |
| KR101666605B1 (ko) | 2015-02-13 | 2016-10-18 | 한국과학기술원 | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물 |
| CA3001543C (en) | 2015-10-29 | 2023-06-27 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| EP3414319B1 (en) | 2016-02-10 | 2024-07-24 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
| KR101709307B1 (ko) | 2016-10-31 | 2017-02-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물 |
| CN110636846B (zh) * | 2017-05-17 | 2023-05-16 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的喹唑啉吡唑衍生物 |
| JP2020532541A (ja) | 2017-08-31 | 2020-11-12 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法 |
| JP7849948B2 (ja) * | 2018-03-05 | 2026-04-22 | テオン セラピューティクス，インク． | アデノシン受容体アンタゴニストおよびその使用 |
| GB201804922D0 (en) | 2018-03-27 | 2018-05-09 | Ucl Business Plc | Traatment |
| AU2019312296B2 (en) * | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| CN111686239B (zh) * | 2019-03-11 | 2021-12-24 | 中国科学院微生物研究所 | 抗真菌化合物的应用 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| AU2002359365B2 (en) * | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| ES2208063B1 (es) * | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| MXPA04000908A (es) * | 2002-05-30 | 2004-03-26 | King Pharmaceuticals Res & Dev | Compuestos farmaceuticamente activos que tienen estructura de anillo de pirazolotriazolopirimidina triciclica y metodos de uso. |
| WO2004086052A2 (en) | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b) |
| GB0401336D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| CA2646333C (en) | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
-
2007
- 2007-03-16 CA CA2646333A patent/CA2646333C/en active Active
- 2007-03-16 CN CN2007800095071A patent/CN101405003B/zh active Active
- 2007-03-16 US US11/687,236 patent/US7795268B2/en active Active
- 2007-03-16 MX MX2008011828A patent/MX2008011828A/es active IP Right Grant
- 2007-03-16 RU RU2008137279/15A patent/RU2457842C2/ru active
- 2007-03-16 EP EP07758704A patent/EP1996201A2/en not_active Withdrawn
- 2007-03-16 WO PCT/US2007/064182 patent/WO2007109547A2/en not_active Ceased
- 2007-03-16 CA CA2849661A patent/CA2849661A1/en not_active Abandoned
- 2007-03-16 JP JP2009501667A patent/JP5250848B2/ja active Active
- 2007-03-16 KR KR1020087022707A patent/KR101428113B1/ko active Active
- 2007-03-16 AU AU2007227021A patent/AU2007227021B2/en active Active
- 2007-03-16 NZ NZ571324A patent/NZ571324A/en unknown
-
2008
- 2008-09-15 ZA ZA200807894A patent/ZA200807894B/xx unknown
- 2008-09-17 NO NO20083968A patent/NO20083968L/no not_active Application Discontinuation
- 2008-09-17 IL IL194158A patent/IL194158A0/en unknown
-
2010
- 2010-08-10 US US12/853,510 patent/US8188099B2/en active Active
-
2012
- 2012-02-28 US US13/407,616 patent/US8609671B2/en active Active
- 2012-12-07 JP JP2012268193A patent/JP2013049719A/ja active Pending
-
2013
- 2013-10-04 US US14/046,847 patent/US20140243358A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5250848B2 (ja) | 2013-07-31 |
| RU2457842C2 (ru) | 2012-08-10 |
| WO2007109547A3 (en) | 2007-11-29 |
| IL194158A0 (en) | 2009-08-03 |
| WO2007109547A2 (en) | 2007-09-27 |
| CA2849661A1 (en) | 2007-09-27 |
| US8188099B2 (en) | 2012-05-29 |
| CA2646333A1 (en) | 2007-09-27 |
| AU2007227021B2 (en) | 2012-12-20 |
| US20120220608A1 (en) | 2012-08-30 |
| AU2007227021A1 (en) | 2007-09-27 |
| EP1996201A2 (en) | 2008-12-03 |
| US20110184002A1 (en) | 2011-07-28 |
| NZ571324A (en) | 2011-07-29 |
| JP2013049719A (ja) | 2013-03-14 |
| RU2008137279A (ru) | 2010-03-27 |
| KR20080107416A (ko) | 2008-12-10 |
| CN101405003A (zh) | 2009-04-08 |
| ZA200807894B (en) | 2009-05-27 |
| US8609671B2 (en) | 2013-12-17 |
| US7795268B2 (en) | 2010-09-14 |
| US20140243358A1 (en) | 2014-08-28 |
| US20070219221A1 (en) | 2007-09-20 |
| MX2008011828A (es) | 2008-09-29 |
| KR101428113B1 (ko) | 2014-08-07 |
| JP2009530413A (ja) | 2009-08-27 |
| CA2646333C (en) | 2014-06-17 |
| CN101405003B (zh) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007109547A3 (en) | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists | |
| Qaddir et al. | Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies | |
| NO20072733L (no) | Doseformer | |
| WO2010034670A3 (en) | Host cell kinases as targets for antiviral therapies against hcv infection | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| NO20090469L (no) | Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav | |
| MX2020005345A (es) | Un método para inhibir o reducir una infección viral por coronavirus. | |
| NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
| ECSP066791A (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
| EA200900297A1 (ru) | Ингибиторы вируса гепатита с | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| DK2250163T3 (da) | Hepatitis C-virusinhibitorer | |
| WO2010081082A3 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
| ECSP066794A (es) | Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| EA201490654A1 (ru) | Новые ингибиторы вирусной репликации | |
| WO2008076392A3 (en) | Compounds useful as protein kinase inhibitors | |
| WO2007143607A3 (en) | Method of treating atrophic vaginitis | |
| ECSP088793A (es) | Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo | |
| MY145349A (en) | Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor | |
| NO20084411L (no) | Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| MX2013000242A (es) | Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral. | |
| PA8744101A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| NO20055000L (no) | Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger | |
| EA201001100A1 (ru) | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |